李强签署国务院令，《药品管理法实施条例》发布！

Core Viewpoint - The revised "Regulations for the Implementation of the Drug Administration Law of the People's Republic of China" aims to enhance drug innovation, streamline drug approval processes, and strengthen drug safety supervision, marking the first comprehensive revision in over 20 years [3][4]. Group 1: Drug Research and Registration - The new regulations support drug development and innovation guided by clinical value, encouraging the creation of new drugs and their clinical promotion [1][5]. - A fast-track registration process for new drugs has been established, along with clear re-registration procedures and mechanisms for converting prescription drugs to over-the-counter status [1][4]. - Special market exclusivity periods are granted for pediatric and rare disease medications, along with data protection for drugs containing novel chemical components [1][9]. Group 2: Drug Production Management - The regulations enforce strict management of drug contract manufacturing, clarifying the responsibilities of drug marketing authorization holders [2][13]. - Specific management requirements for the production and sale of traditional Chinese medicine (TCM) products have been outlined [2][12]. Group 3: Drug Distribution and Usage - The regulations improve the management of online drug sales, emphasizing the responsibilities of third-party platforms in drug transactions [2][10]. - Medical institutions are required to adhere to strict drug management practices to ensure the quality of drugs used [2][11]. Group 4: Drug Safety Supervision - The regulations specify measures for drug safety supervision and inspection, detailing the process for quality sampling and testing [2][5]. - Strict legal responsibilities for violations have been established to enhance accountability [2][5]. Group 5: Encouragement of Drug Innovation - The revised regulations explicitly encourage innovation by supporting clinical value-oriented drug research and improving the quality and efficacy of generic drugs [6][7]. - Four expedited approval pathways for breakthrough therapies, conditional approvals, and priority reviews have been formally included in the regulations [6][8]. Group 6: Intellectual Property Protection - The regulations strengthen the protection of drug intellectual property, introducing a market exclusivity period for innovative drugs [7][9]. - The exclusivity period for pediatric drugs is capped at two years, while rare disease drugs can receive up to seven years of exclusivity [9]. Group 7: Online Drug Sales Regulation - The regulations clarify the responsibilities and requirements for online drug sales platforms, mandating the establishment of dedicated management systems [11][10]. - The regulations also encourage the implementation of quality management standards for TCM production to enhance the quality of raw materials [11][12]. Group 8: Production Flexibility - The regulations allow for segmented contract manufacturing, enabling more efficient production of innovative drugs that require specialized processes [13][14]. - A pilot program for segmented production of innovative drugs will be initiated in select provinces starting in 2024 [14].